Overview

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Status:
Completed

Trial end date:
2021-03-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan